Aberrant promoter hypomethylation in CLL

Does it matter for disease development?

Garland Michael Upchurch, Staci L. Haney, Rene Opavsky

Research output: Contribution to journalShort survey

6 Citations (Scopus)

Abstract

Over the last 30 years, studies of aberrant DNA methylation in hematologic malignancies have been dominated by the primary focus of understanding promoter hypermethylation. These efforts not only resulted in a better understanding of the basis of epigenetic silencing of tumor suppressor genes but also resulted in approval of hypomethylating agents for the treatment of several malignancies, such as myelodysplastic syndrome and acute myeloid leukemia. Recent advances in global methylation profiling coupled with the use of mouse models suggest that aberrant promoter hypomethylation is also a frequent event in hematologic malignancies, particularly in chronic lymphocytic leukemia (CLL). Promoter hypomethylation affects gene expression and, therefore, may play an important role in disease pathogenesis. Here, we review recent findings and discuss the potential involvement of aberrant promoter hypomethylation in CLL.

Original languageEnglish (US)
Article number182
JournalFrontiers in Oncology
Volume6
Issue numberAUG
DOIs
StatePublished - Aug 11 2016

Fingerprint

Hematologic Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Myelodysplastic Syndromes
DNA Methylation
Tumor Suppressor Genes
Acute Myeloid Leukemia
Epigenomics
Methylation
Gene Expression
Neoplasms

Keywords

  • Chronic lymphocytic leukemia
  • DNA methylation
  • DNA methyltransferases
  • Hematologic neoplasms
  • Hypomethylation
  • Leukemia
  • Mouse models of cancer
  • Promoter methylation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aberrant promoter hypomethylation in CLL : Does it matter for disease development? / Upchurch, Garland Michael; Haney, Staci L.; Opavsky, Rene.

In: Frontiers in Oncology, Vol. 6, No. AUG, 182, 11.08.2016.

Research output: Contribution to journalShort survey

Upchurch, Garland Michael ; Haney, Staci L. ; Opavsky, Rene. / Aberrant promoter hypomethylation in CLL : Does it matter for disease development?. In: Frontiers in Oncology. 2016 ; Vol. 6, No. AUG.
@article{b47b1be7cd464460bf9738835aab9bc6,
title = "Aberrant promoter hypomethylation in CLL: Does it matter for disease development?",
abstract = "Over the last 30 years, studies of aberrant DNA methylation in hematologic malignancies have been dominated by the primary focus of understanding promoter hypermethylation. These efforts not only resulted in a better understanding of the basis of epigenetic silencing of tumor suppressor genes but also resulted in approval of hypomethylating agents for the treatment of several malignancies, such as myelodysplastic syndrome and acute myeloid leukemia. Recent advances in global methylation profiling coupled with the use of mouse models suggest that aberrant promoter hypomethylation is also a frequent event in hematologic malignancies, particularly in chronic lymphocytic leukemia (CLL). Promoter hypomethylation affects gene expression and, therefore, may play an important role in disease pathogenesis. Here, we review recent findings and discuss the potential involvement of aberrant promoter hypomethylation in CLL.",
keywords = "Chronic lymphocytic leukemia, DNA methylation, DNA methyltransferases, Hematologic neoplasms, Hypomethylation, Leukemia, Mouse models of cancer, Promoter methylation",
author = "Upchurch, {Garland Michael} and Haney, {Staci L.} and Rene Opavsky",
year = "2016",
month = "8",
day = "11",
doi = "10.3389/fonc.2016.00182",
language = "English (US)",
volume = "6",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Aberrant promoter hypomethylation in CLL

T2 - Does it matter for disease development?

AU - Upchurch, Garland Michael

AU - Haney, Staci L.

AU - Opavsky, Rene

PY - 2016/8/11

Y1 - 2016/8/11

N2 - Over the last 30 years, studies of aberrant DNA methylation in hematologic malignancies have been dominated by the primary focus of understanding promoter hypermethylation. These efforts not only resulted in a better understanding of the basis of epigenetic silencing of tumor suppressor genes but also resulted in approval of hypomethylating agents for the treatment of several malignancies, such as myelodysplastic syndrome and acute myeloid leukemia. Recent advances in global methylation profiling coupled with the use of mouse models suggest that aberrant promoter hypomethylation is also a frequent event in hematologic malignancies, particularly in chronic lymphocytic leukemia (CLL). Promoter hypomethylation affects gene expression and, therefore, may play an important role in disease pathogenesis. Here, we review recent findings and discuss the potential involvement of aberrant promoter hypomethylation in CLL.

AB - Over the last 30 years, studies of aberrant DNA methylation in hematologic malignancies have been dominated by the primary focus of understanding promoter hypermethylation. These efforts not only resulted in a better understanding of the basis of epigenetic silencing of tumor suppressor genes but also resulted in approval of hypomethylating agents for the treatment of several malignancies, such as myelodysplastic syndrome and acute myeloid leukemia. Recent advances in global methylation profiling coupled with the use of mouse models suggest that aberrant promoter hypomethylation is also a frequent event in hematologic malignancies, particularly in chronic lymphocytic leukemia (CLL). Promoter hypomethylation affects gene expression and, therefore, may play an important role in disease pathogenesis. Here, we review recent findings and discuss the potential involvement of aberrant promoter hypomethylation in CLL.

KW - Chronic lymphocytic leukemia

KW - DNA methylation

KW - DNA methyltransferases

KW - Hematologic neoplasms

KW - Hypomethylation

KW - Leukemia

KW - Mouse models of cancer

KW - Promoter methylation

UR - http://www.scopus.com/inward/record.url?scp=84990029004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990029004&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00182

DO - 10.3389/fonc.2016.00182

M3 - Short survey

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - AUG

M1 - 182

ER -